A Glucosylated BODIPY Uses the GLUT Channel to Target Cancer Cells in In Vitro and In Vivo Models

  • ACS Omega. 2025 Nov 7;10(45):54217-54223. doi: 10.1021/acsomega.5c06410.
Marta Turati  1 ,  Giacomo Biagiotti  2 ,  Cosetta Ravelli  1 ,  Chiara Tobia  1 ,  Jacopo Cardellini  2 ,  Luca Mignani  1 ,  Jacopo Tricomi  2 ,  Debora Berti  2 ,  Stefano Cicchi  2 ,  Barbara Richichi  2 ,  Roberto Ronca  1
Affiliations
  • 1. Department of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.
  • 2. Department of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.
PMID: 41280800 DOI: 10.1021/acsomega.5c06410
Abstract

The conjugation of fluorescent probes to tumor-targeting molecules represents a promising strategy for the development of precision Cancer bioimaging and treatment. Among the different tumor-targeting strategies, the use of d-glucose residues, which exploit the high energy demand of Cancer cells, can enable recognition by a broad spectrum of tumors, thus overcoming limitations related to Cancer heterogeneity. In this study, we combined the distinctive optical properties of BODIPY-based probes with the known tumor-targeting abilities of d-glucose. We report on the characterization of a glucosylated BODIPY, named Glc-BODIPY, and its ability to target different Cancer cell types in both in vitro and in vivo models.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-19331
    WZB117
    99.93%, Glut1 Inhibitor
    target: GLUT
    Research Areas: Cancer